Sarepta Therapeutics (NASDAQ:SRPT) Now Covered by Analysts at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft assumed coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT - Free Report) in a research report report published on Tuesday, Marketbeat.com reports. The firm issued a hold rating and a $136.00 price target on the biotechnology company's stock.

Other equities analysts have also recently issued research reports about the stock. Piper Sandler dropped their price target on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating on the stock in a research report on Wednesday, November 27th. Cantor Fitzgerald raised shares of Sarepta Therapeutics from a "neutral" rating to an "overweight" rating and lifted their price target for the stock from $152.00 to $167.00 in a report on Thursday, November 7th. Evercore ISI lowered their price target on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an "outperform" rating on the stock in a report on Thursday, November 7th. Jefferies Financial Group initiated coverage on shares of Sarepta Therapeutics in a research note on Monday, October 21st. They issued a "buy" rating and a $165.00 price objective for the company. Finally, Robert W. Baird reduced their price target on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an "outperform" rating for the company in a research report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Sarepta Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $176.77.

Sarepta Therapeutics Stock Down 1.2 %

Shares of SRPT traded down $1.34 during trading hours on Tuesday, hitting $108.12. The stock had a trading volume of 329,141 shares, compared to its average volume of 790,054. Sarepta Therapeutics has a 1-year low of $102.15 and a 1-year high of $173.25. The firm has a market capitalization of $10.33 billion, a P/E ratio of 86.70 and a beta of 0.75. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The firm has a 50 day simple moving average of $119.82 and a 200-day simple moving average of $125.11.

Insider Activity

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 1,636 shares of the company's stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the sale, the director now owns 5,880 shares in the company, valued at approximately $738,234. This represents a 21.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the sale, the director now owns 22,840 shares in the company, valued at approximately $2,851,345.60. The trade was a 31.49 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.70% of the company's stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Institutional investors have recently made changes to their positions in the company. Manchester Capital Management LLC lifted its position in Sarepta Therapeutics by 86.6% during the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock valued at $29,000 after purchasing an additional 110 shares during the period. MassMutual Private Wealth & Trust FSB raised its position in Sarepta Therapeutics by 169.6% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 156 shares during the period. Sunbelt Securities Inc. raised its position in shares of Sarepta Therapeutics by 446.2% during the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company's stock valued at $35,000 after purchasing an additional 232 shares during the period. Huntington National Bank raised its position in shares of Sarepta Therapeutics by 150.9% during the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock valued at $36,000 after purchasing an additional 175 shares during the period. Finally, Newbridge Financial Services Group Inc. purchased a new position in Sarepta Therapeutics during the fourth quarter valued at $36,000. Hedge funds and other institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.